Testing & Certification Services
All research in Testing & Certification Services — 5 reports.
ALS Limited is a global laboratory-testing group that earns most of its revenue from Life Sciences yet a disproportionate share of margin from minerals-related Commodities testing, so a diversified TIC provider still trades, at key moments, like a high-quality miner's service proxy. FY26 delivered record revenue of A$3.32 billion and an 18.0% underlying EBIT margin, hitting the FY27 strategic targets a year early, but at A$23.36 the stock trades near 37 times trailing EPS with the margin of safety put at zero. Rating Hold: a strong dual-engine testing franchise whose price already discounts commodities strength, acquisition repair and future hub productivity, leaving little room for disappointment.
SGS SA is the world's broadest publicly listed testing, inspection and certification group, monetizing accreditation, network density and a century-old reputation for independence across more than 2,500 facilities in 115 countries. In 2025 it generated CHF 6.945 billion of sales at a 16.0% adjusted operating margin and converted profit to cash at roughly 1.9x net income, yet at about 25.9x trailing earnings and a 3.6% dividend yield the market already prices the Strategy 27 reacceleration, leaving no conservative margin of safety against a CHF 80-84 fair value. Rating Hold: a high-quality TIC compounder whose current price captures most of the Strategy 27 improvement and leaves limited conservative upside.
Intertek Group is a global ATIC (assurance, testing, inspection, certification) provider that sells trust as much as lab work, running a five-division Total Quality Assurance portfolio across consumer products, supply chains, food, infrastructure and energy. In 2025 it grew revenue 4.3% at constant currency to GBP 3.43 billion and lifted its adjusted operating margin 90 basis points to 18.1%, yet at around GBP 57 the shares now trade chiefly on EQT's GBP 60.0 indicative cash proposal rather than on operating momentum, leaving little standalone margin of safety against a roughly 35-40% downside if the bid lapses. Rating Hold: a proven quality compounder whose current price already capitalizes most of the margin-improvement and strategic-optionality story, leaving thin reward for fresh capital.
Bureau Veritas is an 1828-founded global testing, inspection and certification network operating across six lines that sells institutional trust, with 2025 revenue of EUR 6.47 billion, a 16.3% adjusted operating margin, and EUR 824 million of free cash flow. The real question is durability rather than quality: after a strong 2024 of 10.2% organic growth, Q1 2026 organic growth slowed to 4.5% and management trimmed full-year guidance on Government Services contract exits, leaving the stock at about 18.4x 2025 adjusted EPS of EUR 1.42 with a conservative fair value near EUR 23 already below the current EUR 26.16 price. Rating Hold: Bureau Veritas remains a strong TIC franchise, but the current price already discounts much of the LEAP 28 plan before 2026 re-acceleration is proven.
Eurofins Scientific, founded in 1987 by Gilles Martin in Nantes, France and headquartered in Luxembourg, is the world's largest testing, inspection and certification (TIC) leader, spanning food, environment, pharma, clinical diagnostics and consumer products, with roughly 64,000 employees and 900+ laboratories across 50+ countries; FY2025 revenue was EUR 7.30 B (+5.0% reported / +4.1% organic), adjusted EBITDA margin 22.5% (mature business 24.3%) and EPS EUR 2.31 (+24%), while the Martin family holds 32.9% economic interest / 65.8% voting power through Analytical Bioventures. Following Muddy Waters' June 2024 short report alleging self-dealing—which the company fully rebutted—the market's governance discount has yet to fully clear. Rating Watch: a high-quality TIC leader that is reasonably-to-richly valued and awaits a pullback rather than entry at the current price.